Branton v. Bristol-Myers Squibb Company, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Branton v. Bristol-Myers Squibb Company, Inc.

Sort by

Viewing results 1‒25 of 424

US politics & policy
US targets 10 drugs for pricing negotiations in crackdown on costs
...Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
August 29, 2023
Bristol-Myers Squibb Co
Bristol-Myers Squibb to acquire cancer drugmaker Turning Point for $4.1bn
...Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines....
June 3, 2022
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
AbbVie Inc
Blockbuster AbbVie drug Humira to face competition in US for first time
...Merck, Bristol Myers Squibb and Amgen have all used these aggressive tactics to protect blockbuster drugs from competition, said O’Reilly....
January 31, 2023
Drug prices
US drugmakers withdraw from NHS pricing agreement as costs soar
...Last year, US drugmaker Bristol Myers Squibb said it could divert investment away from the UK because of the increasing clawbacks....
January 16, 2023
Pharmaceuticals sector
Big Pharma fights patent disclosure demand from investors
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
February 26, 2023
Pharmaceuticals sector
Merck in talks over $40bn deal for cancer biotech SeaGen
...SeaGen also recently signed a partnership with French drugmaker Sanofi and has agreements with Takeda and Bristol Myers Squibb among others. SeaGen declined to comment....
July 7, 2022
FT Live
Due Diligence Live
Where leaders in investment and finance meet
Tuesday, 8 OctoberLondon, UK
Berkshire Hathaway Inc
Buffett bought $1bn stake in Activision weeks before Microsoft deal
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
February 14, 2022
News in-depthElon Musk
How Elon Musk could fund his $43bn Twitter takeover
...Even though its balance sheet is smaller than rivals such as JPMorgan and Bank of America, it has tapped its relationship with Japan’s Mitsubishi UFJ to finance huge loans before, including $33.5bn for Bristol-Myers...
April 15, 2022
Merck & Co Inc
Merck to buy Acceleron Pharma for $11.5bn
...The company markets Reblozyl, a drug that treats anaemia in certain blood disorders, in the US, Europe and Canada in collaboration with Bristol-Myers Squibb, which owns an 11.5 per cent stake in Acceleron...
September 30, 2021
LexJohnson & Johnson Co Inc
J&J: new CEO offers continuity Premium content
...J&J shares trade on a multiple of 18 times forward earnings, well above Pfizer’s 12 times and Bristol-Myers Squibb’s 9 times. Duato will have to deliver on the vaccine front to justify this premium....
August 20, 2021
News in-depthPharmaceuticals sector
Merck on deals hunt as patent cliff looms for top cancer drug
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
October 6, 2021
Berkshire Hathaway Inc
Buffett dumps bulk of his remaining Wells Fargo shares
...Berkshire reduced its stakes in drugmakers including Merck, Bristol-Myers Squibb and AbbVie in the first quarter, cut more than half of its holding in oil major Chevron, and sold the entirety of its positions...
May 17, 2021
Berkshire Hathaway Inc
Berkshire reveals confidential bets on Verizon and Chevron
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
February 17, 2021
Covid-19 vaccines
Merkel rejects US move to waive patents on vaccines
...The chief executive of Bristol-Myers Squibb described the US government’s support for waiver as “very concerning” during an interview at the FT US Pharma and Biotech Summit on Thursday....
May 6, 2021
Berkshire Hathaway Inc
Buffett pulls back on banks and bets on drugmakers
...Berkshire added 21.3m shares of AbbVie, 30m shares of Bristol-Myers Squibb, 22.4m shares of Merck and 3.7m shares of Pfizer to its $245bn equity portfolio, according to a filing with the US securities regulator...
November 17, 2020
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Due Diligence
The hedge fund that took on Wall Street’s powerful machinery Premium content
...(Bloomberg) News round-up Bristol-Myers Squibb to buy heart treatment maker for $13.1bn (FT + Lex) France’s Engie sells €3.4bn stake in Suez (FT) HPS raises $9bn as investors race into direct lending...
October 6, 2020
AbbVie Inc
US regulator clears AbbVie’s $63bn deal for Allergan
...Other deals included Bristol-Myers-Squibb’s $74bn takeover of biotech group Celgene and Pfizer’s $11.4bn acquisition of Array BioPharma....
May 6, 2020
Celgene Corp
Amgen to buy Celgene’s Otezla in $13.4bn deal
...Shares in Bristol-Myers Squibb jumped 4.2 per cent to $48.52 in morning trading in New York, while Amgen stock rose 2.2 per cent to $203.42....
August 26, 2019
Gilead Sciences Inc
Gilead buys cancer therapy specialist Forty Seven in $4.9bn deal
...Early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June....
March 2, 2020
Tesla Inc
Hedge fund Renaissance built stake ahead of Tesla share surge
...Filings with the Securities and Exchange Commission show Renaissance owned almost 4m Tesla shares at the end of last year, making the Elon Musk company its second-largest holding behind Bristol-Myers Squibb...
February 18, 2020
Mergers & Acquisitions
Wall Street M&A fees drop by more than $500m in 2019
...While those takeovers do not generate the same fanfare as marquee transactions such as Bristol-Myers Squibb’s $93.4bn takeover of rival drugmaker Celgene, they are critical fee generators for advisers....
January 17, 2020
Drug prices
Pfizer and other drugmakers start 2020 with price rises
...drug price increases at the start of the year included a 7.4 per cent rise in the price of Humira, AbbVie’s blockbuster drug for treating inflammatory diseases, and a 6 per cent increase in the price of Bristol-Myers...
January 3, 2020
Due Diligence
Warren Buffett: New year, new deal? Premium content
...A chart to start the year with: corporate fee payers Bristol-Myers Squibb’s $93bn takeover of rival drugmaker Celgene was one of the first megadeals out of the gate last year, and it proved incredibly lucrative...
January 8, 2020
Due Diligence
Bonuses at risk as M&A fees slide Premium content
...The bank nonetheless enjoyed a blockbuster payday for its work advising Bristol-Myers Squibb on its takeover of Celgene, a deal that generated Morgan Stanley an $82m advisory fee JPMorgan Chase reported...
January 17, 2020
LexMergers & Acquisitions
AbbVie/Allergan: not looking good Premium content
...Earlier this year, Bristol-Myers Squibb acquired fading biotech star Celgene while promising a massive near-term boost in profits per share....
June 25, 2019

Previous pagePage 1 of 17Next page